协同持续的药物释放系统基于固定的Rhamnus frangulaL. 植物提取物成层叠的双氧化物覆盖生物相容的水凝
Ana-Lorena Neagu1,2, Anamaria Zaharia1, Octavian Dumitru Pavel3
1National Institute for Research and Development & Chemistry and Petrochemistry-ICECHIM, Bucharest, Spl. Independentei No. 202, Sector 6, 060021 Bucharest, Romania.
Pharmaceutics
|July 29, 2023
概括
这项研究表明,通过使Rhamnus frangula L. phytoextract在分层的双氧化物和水凝中固定,增强可控药物释放的协同效应. 复合水凝显示了改进的特性和持续释放行为.
科学领域:
- 材料科学 材料科学 材料科学
- 生物医学工程 生物医学工程
- 药理学 药理学是指药理学的学科.
背景情况:
- 植物提取物具有治疗潜力,但需要有效的输送系统.
- 层状双氧化物 (LDHs) 可以固定活性化合物.
- 生物相容的水凝 (HGs) 适用于药物输送应用.
研究的目的:
- 调查LDH中固定Rhamnus frangula L. (RfL) 植物提取物和随后封装到基于PEGDA的HG中的协同效应.
- 为了描述由此产生的水凝复合物,并评估它们的胀性,质性和体外持续释放性.
- 探索这些复合HG在药物应用中的潜力,以控制药物输送.
主要方法:
- 通过重建方法将RfL植物提取物固定到LDH中.
- 使用激素聚合,将LDHs-RfL封装成基于PEGDA的HG.
- 使用现代分析技术对水凝复合材料进行表征.
- 在pH 6.8下进行体外释放研究,以评估持续释放动力学.
主要成果:
- 水凝复合剂显示改善了胀和风湿,增加了LDHs-RfL含量.
- 在pH 6.8的体外释放研究表明,RfL植物提取物持续释放.
- PEGDA网络和LDH颗粒的协同效应增强了缓释行为.
- 释放动力学遵循一个扩散控制模型.
结论:
- 开发的水凝复合材料表现出增强的性能和可控释放能力.
- LDHs和水凝矩阵之间的协同相互作用改善了药物保留和释放.
- 这些复合水凝对控制药物输送系统中的药物应用具有前景.
相关概念视频
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...